Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Scholar Rock sees stock soar after announcing positive SMA results

By Brian Buntz | October 28, 2020

Scholar Rock logoA monoclonal antibody that blocks the activation of the skeletal muscle protein myostatin could be novel muscle-directed therapy for spinal muscular atrophy patients. 

Cambridge, Mass.–based Scholar Rock (NSDQ:SRRK), which is developing the SRK-015 investigational antibody, saw its shares more than double to $30.02 apiece yesterday. SRK-015 could lead to the formation of a new treatment category that targets and supports muscle fiber growth, according to the company. 

The antibody has shown promise in a six-month clinical trial involving patients with type 2 (intermediate) and type 3 (mild) spinal muscular atrophy. Notably, all three treatment cohorts involved in the study reported improved muscle function. 

Scholar Rock specializes in treating serious diseases with links to protein growth factors. Spinal muscular atrophy, which results from the lack of survival motor neuron (SMN) protein, is such a disease.

A double-blind high-dose randomized portion of the trial resulted in a 5.6 point improvement from baseline after six months on the Hammersmith Functional Motor Scale Expanded (HFMSE). By contrast, a low-dose arm resulted in a 2.4 gain on the scale. 

Scholar Rock reported no safety concerns in the trial. 

FDA has granted SRK-015 an orphan drug designation and a rare pediatric disease designation. 

Scholar Rock anticipates 12-month data from the trial in the second quarter of 2021. 

In 2018, Scholar Rock teamed up with Gilead Sciences to develop therapies to treat fibrotic diseases. 


Filed Under: clinical trials, Drug Discovery, Orphan Drugs
Tagged With: Gilead Sciences, Scholar Rock, SMA, spinal muscular atrophy, SRK-015
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Bristol Myers Squibb
FDA approves Bristol-Myers Squibb immunotherapy for gastric cancer
eye
Investigational drug gives sight to patient with inherited form of blindness 
RedHill
Why RedHill Biopharma is expanding its focus on infectious disease
OncoSec eyes next steps with its cancer immunotherapy candidate

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Medtech100 Index
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50